Multiple PMO-CPP Conjugates with Cleavable Linkers

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Antisense oligonucleotides (AONs), particularly phosphorodiamidate morpholino oligonucleotides (PMOs), face challenges with poor uptake in skeletal and cardiac muscle cells, leading to ineffective gene modulation, and exhibit increased toxicity when conjugated with cationic cell-penetrating peptides (CPPs).

Innovation Solution

Development of multiple PMO-CPP conjugates with cleavable linkers, incorporating glutamic acid and peptidase cleavage sites, such as Phenylalanine-Lysine, to reduce steric hindrance and toxicity, allowing for enhanced exon skipping efficiency with a safer margin by releasing PMOs from CPPs within cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If PMOs are conjugated with cationic cell-penetrating peptides (CPPs) to enhance uptake into skeletal and cardiac muscle cells, then cellular uptake is improved, but toxicity increases

Engineering Contradiction:
Improvecellular uptake efficiencyVSAvoidtoxicity
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention divides the single PMO-CPP conjugate into multiple separate PMO moieties attached to the CPP. This segmentation allows the CPP to maintain its cell-penetrating function while distributing the PMO load, reducing steric hindrance and toxicity. The multiple PMOs work collectively to achieve the desired gene modulation effect without the adverse effects of a single large conjugate.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The invention changes the structural parameters of the conjugate by attaching multiple smaller PMO moieties instead of one large PMO. This parameter change in the architecture of the conjugate (from 1:1 to multi:1 ratio) improves cellular uptake efficiency while reducing toxicity by minimizing steric hindrance and optimizing the CPP-PMO interaction.

Inventive Principle:
Principle #35Parameter changes

2Object-affected harmful factors

If multiple PMO moieties are attached to CPP to reduce steric hindrance and toxicity, then safety margin is improved, but conjugate complexity increases

Engineering Contradiction:
ImprovetoxicityVSAvoidconjugate structure complexity
Core Design Contradiction:
Object-affected harmful factorsVSDevice complexity

Solution Approach 1:

The conjugate structure is segmented into multiple identical or similar PMO-CPP units rather than one complex single unit. This segmentation approach, while increasing the number of components, actually simplifies the design by using repeating modular units that can be synthesized and characterized more easily than a single complex conjugate.

Inventive Principle:
Principle #1Segmentation

3Reliability

If single PMO-CPP conjugates are used to achieve exon skipping, then gene modulation is achieved, but the safety margin is reduced due to high toxicity

Engineering Contradiction:
Improveexon skipping efficacyVSAvoidtoxicity
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The single PMO-CPP conjugate is segmented into multiple PMO moieties attached to the CPP. This segmentation maintains the exon skipping efficacy by preserving the functional PMO units while reducing toxicity through decreased steric hindrance and optimized cellular uptake, thereby improving the safety margin.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The invention changes the stoichiometric parameters of the conjugate from a 1:1 ratio to a multi:1 ratio of PMO to CPP. This parameter change optimizes the balance between efficacy (maintaining sufficient PMO for exon skipping) and safety (reducing toxicity through better distribution and reduced steric hindrance).

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The multiple PMO-CPP conjugates demonstrate improved exon skipping efficacy and safety, achieving a higher safety margin and efficacy compared to single PMO-CPP constructs, with reduced toxicity and increased efficiency in gene modulation, including in skeletal and cardiac muscle cells.

Implementation Method 1

incorporating glutamic acid and peptidase cleavage sites, such as Phenylalanine-Lysine

Methodology Applied
Scientific EffectPeptidase cleavage: Enzyme

Data Source

PatentEP3151841B1Multiple oligonucleotide moieties on peptide carrier
Publication Date: 2022.10.19 GENZYME CORP
  • EP3151841B1 patent drawingFigure 1
  • EP3151841B1 patent drawingFigure 2
  • EP3151841B1 patent drawingFigure 3

AI summary

The present disclosure relates to antisense oligonucleotides (AONs), such as phosphorodiamidate morpholino oligonucleotides (PMOs). The present disclosure further relates to the conjugation of multiple PMOs to cationic cell penetrating peptides (CPPs) to enhance the uptake of PMOs into skeletal and cardiac muscle cells.